AstraZeneca Buys Second Amgen Biologics Manufacturing Facility

By Pharma News - DCAT Publisher

October 19, 2016

AstraZeneca has purchased a second biologics manufacturing facility in Longmont, Colorado from Amgen that will be used to support AstraZeneca’s existing operations at its nearby Boulder, Colorado site. AstraZeneca first purchased the Boulder facility from Amgen in September of 2015. Financial terms of both acquisitions were not disclosed.

The integration of the two manufacturing facilities will provide AstraZeneca and MedImmune, AstraZeneca's global biologics research and development arm, with flexible biological manufacturing capacity for new treatments, AstraZeneca said. The site will be staffed over time and according to business needs as the company’s pipeline matures and expansions are deemed necessary.

Currently, the Boulder facility is undergoing refurbishment and infrastructure improvements. Once complete, the site is expected to be operational and licensed for commercial production by late 2017, providing for additional capacity within the company’s biologics operations.